Temocapril hydrochloride | CAS#110221-44-8 | temocaprilat prodrug

MedKoo Cat#: 462077 | Name: Temocapril hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Temocapril is a prodrug of the ACE inhibitor, temocaprilat (IC50 = 3.6 and 7.6 nM in isolated rat lung and aorta, respectively).1 Upon oral administration it is rapidly deesterified to the active form, which remains long acting until excreted in bile and urine.1 In clinical trials, it has been used to reduce blood pressure, improve endothelial dysfunction, and prevent vascular remodeling, as well as improve insulin sensitivity and renal function in certain hypertensive or diabetic conditions.

Chemical Structure

Temocapril hydrochloride

CAS#110221-44-8

Theoretical Analysis

MedKoo Cat#: 462077

Name: Temocapril hydrochloride

CAS#: 110221-44-8

Chemical Formula: C23H29ClN2O5S2

Exact Mass: 512.1206

Molecular Weight: 513.06

Elemental Analysis: C, 53.84; H, 5.70; Cl, 6.91; N, 5.46; O, 15.59; S, 12.50

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Temocapril hydrochloride; Temocapril HCl; CS 622; CS-622

IUPAC/Chemical Name

1,4-Thiazepine-4-(5H)-acetic acid, 6-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, monohydrochloride, (2S-(2alpha,6beta(R*)))-

InChi Key

XDDQNOKKZKHBIX-ASBZXGSUSA-N

InChi Code

InChI=1S/C23H28N2O5S2.ClH/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27;/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27);1H/t17-,18-,20-;/m0./s1

SMILES Code

Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@H]2CS[C@@H](CN(CC(=O)O)C2=O)c3cccs3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 513.06 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: No effects on sleep of a histamine H1-receptor antagonist: temelastine. K Adam, I Oswald Br J Clin Pharmacol. 1986 Dec; 22(6): 718–720. doi: 10.1111/j.1365-2125.1986.tb02963.x PMCID: PMC1401224 2: Non-invasive instrumental techniques to detect terfenadine and temelastine induced suppression of histamine weals in man. L Shall, R Marks Br J Clin Pharmacol. 1987 Oct; 24(4): 409–413. doi: 10.1111/j.1365-2125.1987.tb03192.x PMCID: PMC1386301 3: Temelastine does not affect theophylline pharmacokinetics in normal subjects. B G Charles, J J Schneider, R L Norris, P J Ravenscroft Br J Clin Pharmacol. 1987 Nov; 24(5): 673–675. doi: 10.1111/j.1365-2125.1987.tb03229.x PMCID: PMC1386342 4: Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system. E. A. Brown, R. Griffiths, C. A. Harvey, D. A. Owen Br J Pharmacol. 1986 Mar; 87(3): 569–578. doi: 10.1111/j.1476-5381.1986.tb10199.x PMCID: PMC1916561 5: Characteristics of the binding of [3H]-mepyramine to intact human U373 MG astrocytoma cells: evidence for histamine-induced H1-receptor internalisation. S. Hishinuma, J. M. Young Br J Pharmacol. 1995 Nov; 116(6): 2715–2723. doi: 10.1111/j.1476 5381.1995.tb17232.x PMCID: PMC1909113 6: Modulation of antagonist binding to histamine H1-receptors by sodium ions and by 2-amino-2-hydroxymethyl-propan-1,3-diol HCl. W. J. Gibson, T. W. Roques, J. M. Young Br J Pharmacol. 1994 Apr; 111(4): 1262–1268. doi: 10.1111/j.1476 5381.1994.tb14882.x PMCID: PMC1910162 7: Calcium-dependence of histamine- and carbachol-induced inositol phosphate formation in human U373 MG astrocytoma cells: comparison with HeLa cells and brain slices. J. A. Arias-Montaño, V. Berger, J. M. Young Br J Pharmacol. 1994 Feb; 111(2): 598–608. doi: 10.1111/j.1476-5381.1994.tb14779.x PMCID: PMC1909978 8: Inhibition by cations of antagonist binding to histamine H1-receptors: differential effect of sodium ions on the binding of two radioligands. J. M. Treherne, J. S. Stern, W. J. Flack, J. M. Young Br J Pharmacol. 1991 Jul; 103(3): 1745–1751. doi: 10.1111/j.1476-5381.1991.tb09857.x PMCID: PMC1907796 9: [3H]-(+)-N-methyl-4-methyldiphenhydramine, a quaternary radioligand for the histamine H1-receptor. J. M. Treherne, J. M. Young Br J Pharmacol. 1988 Jul; 94(3): 797–810. doi: 10.1111/j.1476-5381.1988.tb11591.x PMCID: PMC1854022 10: Effects of administration of histamine and its H1, H2, and H3 receptor antagonists into the primary somatosensory cortex on inflammatory pain in rats Esmaeal Tamaddonfard, Nasrin Hamzeh-Gooshchi Iran J Basic Med Sci. 2014 Jan; 17(1): 55–61. PMCID: PMC3938887